INVESTORS

Cool Flame Bio is raising a late Seed round to fund first‑in‑human studies and expand clinical validation of our CIPN platform.

Proceeds will support FIH clinical studies in CIPN and preparation for a subsequent Series A focused on formal, sponsor‑led trials and early commercialization. 

Actively engaging with specialist biotech VCs, family offices, and strategic partners.